SOPHiA GENETICS announced that Instituto Mário Penna is live on the SOPHiA DDM? Platform. Located in Belo Horizonte, Brazil, the Instituto Mário Penna will use SOPHiA GENETICS' technology to advance its testing, research, and advance data-driven diagnoses and treatment decisions for blood-related cancers and disorders.

Instituto Mário Penna has implemented the SOPHiA DDM? Platform to improve its onsite testing capabilities and to inform more data-driven treatment plans. Advances in diagnostics and treatment of blood cancers depend on timely, cost-effective, and reliable sequencing data.

The SOPHiA DDM? Platform uses NGS to target key variants from FFPE, blood, or bone marrow samples helping lead to fast and accurate detection of variants associated with the disease. The SOPHiA DDM?

Platform is specifically designed to compute a wide array of genomic variants and continually hones its machine learning algorithms to detect genomic variants associated with rare and challenging cases. Additionally, the SOPHiA DDM? Platform delivers results that are nearly 100% reproducible to provide consistent inter- and intra-run results, ensuring stable and trustworthy sequencing data.